Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Abstract
Authors
M. Charokopou H. Vioix B. Verheggen L.A. Eddowes M. Griffiths Z. Gabriel K. Tolley D. Franks